Table 3.
Baseline |
Follow-up |
|||||||
---|---|---|---|---|---|---|---|---|
Control |
Intervention |
Control |
Intervention |
|||||
M | SD | SD | SD | M | SD | M | SD | |
With any partner regardless of serostatus | ||||||||
UAI | 10.5 | 15.5 | 6.2 | 11.5 | 6.3 | 13.4 | 4.1 | 10.6 |
UIAI | 3.3 | 6.9 | 3.4 | 7.6 | 1.9 | 4.6 | 2.1 | 6.1 |
URAI | 6.0 | 9.4 | 2.9 | 6.2 | 3.0 | 6.9 | 2.0 | 5.5 |
UIOI | 11.9 | 14.7 | 9.8 | 13.6 | 6.2 | 8.1 | 7.5 | 8.4 |
UROI | 14.4 | 17.2 | 7.6 | 8.7 | 7.5 | 9.4 | 6.7 | 9.1 |
With partner of positive/unknown serostatus | ||||||||
UAI | 1.5 | 4.5 | 2.3 | 5.2 | 0.8 | 1.9 | 0.3 | 0.9 |
UIAI | 0.2 | 0.8 | 1.0 | 2.6 | 0.2 | 0.5 | 0.2 | 0.9 |
URA | 1.1 | 3.0 | 1.5 | 4.7 | 0.5 | 1.3 | 0.2 | 0.8 |
UIOI | 2.2 | 4.1 | 3.5 | 6.3 | 1.5 | 2.9 | 1.2 | 2.3 |
UROI | 3.0 | 6.8 | 3.0 | 5.4 | 1.4 | 2.8 | 0.9 | 2.3 |